Why Covid-19 Vaccine Sales Are Crushing Biotech Billionaire Fortunes

Key Concepts

• Biotech Firms: Companies like Moderna and BioNTech that develop drugs and vaccines using biological processes.
• mRNA Vaccines: A type of vaccine technology that uses messenger RNA to teach the body's cells how to make a protein that triggers an immune response, specifically for COVID-19 in this context.
• Market Capitalization: The total value of a company's outstanding shares, calculated by multiplying the share price by the number of shares.
• Three Comma Club: A colloquial term referring to billionaires.
• Vaccine Skeptic: An individual who expresses doubts about the safety, efficacy, or necessity of vaccines.
• US Food and Drug Administration (FDA): The federal agency responsible for regulating and approving drugs, vaccines, and medical devices in the United States.
• Centers for Disease Control and Prevention (CDC): The national public health agency of the United States, providing health information and recommendations.
• Advisory Committee for Immunization Practices (ACIP): A committee that develops recommendations for vaccine use in the U.S.
• Booster Shot: An additional dose of a vaccine given after the primary series to enhance or extend immunity.

Decline of COVID-19 Vaccine Fortunes

In August 2021, biotech firms Moderna and BioNTech experienced a peak in their financial success due to their highly profitable COVID-19 vaccines. At this time, Moderna's market capitalization reached $195 billion, surpassing that of Merck, a company with over three times its revenues. Forbes identified eight billionaires from these two companies, with a combined net worth of $116 billion. Notable figures included identical twin brothers Andreas and Thomas Strüngmann, early BioNTech backers, each with a $31 billion fortune, and Moderna President Steven Hoge, with a $2.6 billion net worth.

However, this prosperity has significantly diminished. Moderna's stock now trades 95% below its peak, and BioNTech's is 78% below its peak. Of the original eight billionaires, five remain in the "three comma club," but their combined wealth has plummeted to $28.8 billion, less than a third of their former value. This decline is attributed to a "one-two punch" of plunging vaccination rates and governments' reluctance to continue funding vaccine purchases.

Financial Reliance on COVID-19 Vaccines

Despite initial promises during the pandemic era of developing new mRNA vaccines for a range of diseases from HIV to influenza, both Moderna and BioNTech remain heavily dependent on COVID-19 vaccine sales for their revenue. Last year, 95% of Moderna's $3.2 billion revenue came from COVID-19 vaccine sales. Similarly, 88% of BioNTech's $3 billion revenue was derived from these sales. Evan Seagerman, a senior biotech and pharma analyst at Capital Markets, noted that "even before RFK was making noise, you weren't seeing a ton of use of co vaccines," indicating a pre-existing trend of declining demand.

Plunging Vaccination Rates

Vaccination rates in the U.S. and globally have seen a significant drop since late 2021.

• By October 2022, only 34% of Americans had received a COVID-19 booster shot, a steep decline from the 80% who had received at least one initial dose.
• Globally, by December 2023, only 32% of people had received at least one booster, compared to 67% who received the initial vaccines, according to the World Health Organization (WHO).
• Uptake of subsequent boosters has remained low. CDC data indicates that only 23% of Americans received a COVID-19 booster for the 2023-24 season by August 2024.
• Even among the elderly, who are more vulnerable, the rate was not significantly higher, with only 40% of Americans over 65 receiving the booster last year.

Political and Policy Impact

The political landscape, particularly the appointment of Robert F. Kennedy Jr. (RFK Jr.) as Donald Trump's Secretary of Health and Human Services, has introduced significant uncertainty and disruption. RFK Jr., a vocal vaccine skeptic, now oversees the US Food and Drug Administration (FDA). Since his confirmation in February, he has initiated widespread changes:

• Fired thousands of federal healthcare employees, including the directors of the Centers for Disease Control and Prevention (CDC).
• Dismissed all 17 members of the Advisory Committee for Immunization Practices (ACIP), which issues vaccine recommendations.
• Replaced these experts with a handpicked panel of "vastly less experienced advisers," including two outspoken opponents of COVID-19 vaccines.

These administrative changes are expected to further depress vaccination numbers. Recent policy shifts also reflect this trend:

• In August, the FDA approved Moderna and BioNTech's most recent COVID-19 vaccines but restricted their use to adults over 65 years old. Younger individuals are only recommended to receive the vaccine if they are at high risk of severe complications, a departure from previous policy that approved the shot for all adults.
• On September 19th, the newly constituted, less mainstream ACIP considered requiring a prescription for all COVID-19 vaccines, which would have significantly complicated access to routine booster shots. However, the panel ultimately decided against this measure.

Conclusion

The once-booming fortunes of biotech giants Moderna and BioNTech, driven by COVID-19 vaccine sales, have dramatically reversed. This decline is primarily due to plummeting global vaccination rates, reduced government funding for vaccines, and significant political interference, particularly from Robert F. Kennedy Jr.'s appointment and subsequent policy changes within key U.S. health agencies. Despite earlier ambitions for diverse mRNA vaccine applications, both companies remain overwhelmingly reliant on their COVID-19 vaccine portfolios, facing a challenging future marked by diminished demand and a shifting regulatory environment. The specific details regarding stock performance, billionaire wealth, revenue reliance, and vaccination statistics underscore the profound impact of these converging factors on the biotech industry.